Post Reply
1101-1120 of 10899
Major acquisitions is happening in the 1H13. .....can propel the price much higher,tgt 1.80...... thats what CS said. Now can accumulate piecemeal.
alexmay ( Date: 18-Dec-2012 09:49) Posted:
|
Not a bad price. I bought 1.14 sold 1.23 and bought again 1.24. Will wait to sell when it reaches my right price. Lol.
In the end my brokers was smiling broadly. But he also laughed because he bought too. Hahaha.
Those who missed, better look for other counters because it may take some holding and staying power. Lol.
alexmay ( Date: 18-Dec-2012 09:49) Posted:
|
Not BUYING this stock for sure. Advertise too much. Like " Trap" . If readers follow the advice of some for this stock, just look at your opportunity costs.
e.g. Yanlord
TT Intl
Ho Bee
This forum only " real experts" : TonyLim.
bought some at 1.24.
Scoop some today. Good luck.
yiming2000 ( Date: 18-Dec-2012 02:15) Posted:
Please scoop more, everybody. Keep scooping.  |
|
Please scoop more, everybody. Keep scooping.
really hard to puah thru 1.3 sia....
Volume done at 1.245 and 1.25 are actually higher than last friday. Accumulating clearly going on in anticipation for crossing barrier tomorrow or Wednesday.
Probably big block selling but actually not selling but collecting.
stockmarketmind ( Date: 17-Dec-2012 10:28) Posted:
Most probably for the short term. At this price, maybe need a rest first.
infancybird ( Date: 17-Dec-2012 10:23) Posted:
| Noted big sales block at $1.25 by the i-seller of over million share for sales. Looks like we reach a limit here unless a huge buyer emerges. |
|
|
|
Stock should soar if break current resistance. Riding in excellent fundamentals!
Most probably for the short term. At this price, maybe need a rest first.
infancybird ( Date: 17-Dec-2012 10:23) Posted:
Noted big sales block at $1.25 by the i-seller of over million share for sales. Looks like we reach a limit here unless a huge buyer emerges.
infancybird ( Date: 13-Dec-2012 15:57) Posted:
This big i-seller is still out there but he seems to have about to exhaust his ammo( selling 100 lot at one go at time) ....need to buy up all that he is planning to sell to break out of this tug of war. Glad to see greater and greater buy volume.
|
|
|
|
Noted big sales block at $1.25 by the i-seller of over million share for sales. Looks like we reach a limit here unless a huge buyer emerges.
infancybird ( Date: 13-Dec-2012 15:57) Posted:
This big i-seller is still out there but he seems to have about to exhaust his ammo( selling 100 lot at one go at time) ....need to buy up all that he is planning to sell to break out of this tug of war. Glad to see greater and greater buy volume.
raykee ( Date: 12-Dec-2012 16:11) Posted:
| Hai kana sold down again... |
|
|
|
hah just closed my position for profits..
contrary to your strategy, i'll re-enter when there's opportunity.. but this counter still has potentials for upside i believe..
bishan22 ( Date: 16-Dec-2012 13:07) Posted:
Will scoop more if it hits 1.25 and above.
skk888 ( Date: 10-Dec-2012 12:13) Posted:
| Seems like its going to move.. Re entered again. :) |
|
|
|
FTA agreement with EU to benefit pharmaceuticals. Will Biosensors stand to gain?
Will scoop more if it hits 1.25 and above.
skk888 ( Date: 10-Dec-2012 12:13) Posted:
| Seems like its going to move.. Re entered again. :) |
|
This trading week from Mon 10 Dec to friday 14Dec we saw Biosensor trade between 1.14-1.25 not bad for it to close today at $1.24..still on the uptrend and it has since stopped its daily buybacks.So nest week by then all contra or those who cant hold should be out expect Biosensors to cross $1.30 easily
starlene ( Date: 14-Dec-2012 16:14) Posted:
http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_D0DEC4551894A10348257AD3004DD6DC/$file/Biosensors_announces_first_patient_enrolled_in_LEADERS_FREE.pdf?openelement
ricourean ( Date: 14-Dec-2012 12:28) Posted:
Singapore Business Review:
Biosensors International up for a 2013 growth spurt
Chinese market advantage will be the key enabler.
Here's more from Maybank Kim Eng:
The old, old story. The fundamental growth story of Biosensors has not changed - a clinically proven BioMatrixTM drug-eluting stent (DES) threatening to steal market shares from established medical device companies, with a next generation stent (BioFreedomTM) in the pipeline. Despite growing penetration, concerns on future price cuts have taken precedence this year. This overhang has not been totally removed, but we see pockets of growth potential that will spark a revival in 2013.
An edge in the China market. There is a strong China element in Biosensors, evident in its shareholding structure and geographical revenue contribution, with JWMS accounting for about a third of total revenue. In our view, Biosensors has an edge in the Chinese market. The SFDA approval for BioMatrixTM has been taking longer than expected, but our recent conversation with the company suggests that Biosensors is now focusing on bringing on Excel II (improved version of Excel Stent) and its next generation product BioFreedomTM to penetrate the Chinese market instead.
M& A activities in the pipeline? Biosensors has professed its intention to morph into a multi-product medical devices company. While it has strong efforts in R& D, the faster way would be through M& A, and it could do so given a strong balance sheet (net cash of USD332m as at 2QFY3/13). We understand that Biosensors is actively looking at such opportunities and have conducted due diligence on certain companies. It also shared that the US is a market it is keen to get into. We think that there is a high chance of seeing some corporate actions in 2013.
More aggressive marketing in Japan. Lower licensing revenue was a drag on 2QFY3/13 results. Terumo is bent on stepping up marketing
efforts to regain Nobori’s market share, with Biosensors also setting up offices in Japan to help. In our view, the new licensing agreement
favours Biosensors over Terumo with a guaranteed minimum flat fee. I’ll take if you don’t, Reiterate BUY. On 8 Nov 2012, Biosensors initiated its first ever share buybacks since listing. 19.8m shares were repurchased over 17 trading days at SGD1.08-1.17 per share, demonstrating its confidence |
|
|
|
http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_D0DEC4551894A10348257AD3004DD6DC/$file/Biosensors_announces_first_patient_enrolled_in_LEADERS_FREE.pdf?openelement
ricourean ( Date: 14-Dec-2012 12:28) Posted:
Singapore Business Review:
Biosensors International up for a 2013 growth spurt
Chinese market advantage will be the key enabler.
Here's more from Maybank Kim Eng:
The old, old story. The fundamental growth story of Biosensors has not changed - a clinically proven BioMatrixTM drug-eluting stent (DES) threatening to steal market shares from established medical device companies, with a next generation stent (BioFreedomTM) in the pipeline. Despite growing penetration, concerns on future price cuts have taken precedence this year. This overhang has not been totally removed, but we see pockets of growth potential that will spark a revival in 2013.
An edge in the China market. There is a strong China element in Biosensors, evident in its shareholding structure and geographical revenue contribution, with JWMS accounting for about a third of total revenue. In our view, Biosensors has an edge in the Chinese market. The SFDA approval for BioMatrixTM has been taking longer than expected, but our recent conversation with the company suggests that Biosensors is now focusing on bringing on Excel II (improved version of Excel Stent) and its next generation product BioFreedomTM to penetrate the Chinese market instead.
M& A activities in the pipeline? Biosensors has professed its intention to morph into a multi-product medical devices company. While it has strong efforts in R& D, the faster way would be through M& A, and it could do so given a strong balance sheet (net cash of USD332m as at 2QFY3/13). We understand that Biosensors is actively looking at such opportunities and have conducted due diligence on certain companies. It also shared that the US is a market it is keen to get into. We think that there is a high chance of seeing some corporate actions in 2013.
More aggressive marketing in Japan. Lower licensing revenue was a drag on 2QFY3/13 results. Terumo is bent on stepping up marketing
efforts to regain Nobori’s market share, with Biosensors also setting up offices in Japan to help. In our view, the new licensing agreement
favours Biosensors over Terumo with a guaranteed minimum flat fee. I’ll take if you don’t, Reiterate BUY. On 8 Nov 2012, Biosensors initiated its first ever share buybacks since listing. 19.8m shares were repurchased over 17 trading days at SGD1.08-1.17 per share, demonstrating its confidence |
|
the direction seems wrong....
Singapore Business Review:
Biosensors International up for a 2013 growth spurt
Chinese market advantage will be the key enabler.
Here's more from Maybank Kim Eng:
The old, old story. The fundamental growth story of Biosensors has not changed - a clinically proven BioMatrixTM drug-eluting stent (DES) threatening to steal market shares from established medical device companies, with a next generation stent (BioFreedomTM) in the pipeline. Despite growing penetration, concerns on future price cuts have taken precedence this year. This overhang has not been totally removed, but we see pockets of growth potential that will spark a revival in 2013.
An edge in the China market. There is a strong China element in Biosensors, evident in its shareholding structure and geographical revenue contribution, with JWMS accounting for about a third of total revenue. In our view, Biosensors has an edge in the Chinese market. The SFDA approval for BioMatrixTM has been taking longer than expected, but our recent conversation with the company suggests that Biosensors is now focusing on bringing on Excel II (improved version of Excel Stent) and its next generation product BioFreedomTM to penetrate the Chinese market instead.
M& A activities in the pipeline? Biosensors has professed its intention to morph into a multi-product medical devices company. While it has strong efforts in R& D, the faster way would be through M& A, and it could do so given a strong balance sheet (net cash of USD332m as at 2QFY3/13). We understand that Biosensors is actively looking at such opportunities and have conducted due diligence on certain companies. It also shared that the US is a market it is keen to get into. We think that there is a high chance of seeing some corporate actions in 2013.
More aggressive marketing in Japan. Lower licensing revenue was a drag on 2QFY3/13 results. Terumo is bent on stepping up marketing
efforts to regain Nobori’s market share, with Biosensors also setting up offices in Japan to help. In our view, the new licensing agreement
favours Biosensors over Terumo with a guaranteed minimum flat fee. I’ll take if you don’t, Reiterate BUY. On 8 Nov 2012, Biosensors initiated its first ever share buybacks since listing. 19.8m shares were repurchased over 17 trading days at SGD1.08-1.17 per share, demonstrating its confidence
